Loading...
CAR T-Cells in Multiple Myeloma Are Ready for Prime Time
The survival of patients with multiple myeloma (MM) has been dramatically improved in the last decade thanks to the incorporation of second-generation proteasome inhibitors (PI), immunomodulatory drugs (IMID), and, more recently, anti-CD38 monoclonal antibodies (MoAb). Nevertheless, still, a major p...
Na minha lista:
| Udgivet i: | J Clin Med |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7694626/ https://ncbi.nlm.nih.gov/pubmed/33172026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9113577 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|